Amylyx Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Annexon 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07694557, evaluating YKYY025 in Maternal RSV Immunization: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Acumen Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Prothena 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07668804, evaluating TOO-1007 in Geographic Atrophy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Denali Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into JPRN-jRCT2071260009, evaluating Pegcetacoplan in Menopausal Vasomotor Symptoms: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07647198, evaluating Uterine Fibroids in Uterine Fibroids: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Neumora Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07606365, evaluating Geographic Atrophy in Geographic Atrophy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Harmony Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.